Endeavor Health Medical Group
Endeavor Health Medical Group was paid $7.74M by Medicaid between Jan 2018 and Mar 2023, across 143 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 25% of everything it billed.
SKOKIE, IL 60077
Next to other Clinical Medical Laboratory providers in Illinois
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 44,515 | $450K | |
| 2019 | 67,259 | $690K | |
| 2020 | 63,196 | $1.27M | |
| 2021 | 94,914 | $2.10M | |
| 2022 | 171,805 | $2.90M | |
| 2023 | 26,000 | $325K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 25% | 24,578 | 22,034 | $1.96M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 15% | 8,679 | 7,835 | $1.17M |
| 80050 | General health panel | 6.0% | 4,398 | 3,488 | $464K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 5.9% | 5,848 | 5,229 | $456K |
| 84443 | Thyroid stimulating hormone (TSH) | 5.2% | 26,492 | 23,926 | $406K |
| 80053 | Comprehensive metabolic panel | 4.8% | 39,238 | 34,799 | $369K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.6% | 37,773 | 33,379 | $202K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.0% | 18,050 | 15,941 | $157K |
| 80061 | Lipid panel | 2.0% | 27,125 | 23,491 | $151K |
| 87631 | 1.7% | 1,346 | 1,247 | $132K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.6% | 13,071 | 11,816 | $126K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.6% | 21,279 | 17,982 | $126K |
131 more codes
| 87640 | 1.5% | 2,706 | $115K | |
| 86235 | 1.2% | 1,510 | $94K | |
| 84439 | 1.0% | 9,685 | $80K | |
| 80081 | <1% | 1,338 | $76K | |
| 87430 | <1% | 4,791 | $70K | |
| 83970 | <1% | 2,376 | $68K | |
| 87081 | <1% | 12,130 | $66K | |
| 85027 | <1% | 10,757 | $58K | |
| 82607 | <1% | 4,995 | $56K | |
| 86780 | <1% | 3,462 | $56K | |
| 86803 | <1% | 3,315 | $54K | |
| 84153 | <1% | 3,647 | $46K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,072 | $46K |
| 82728 | <1% | 6,557 | $44K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 288 | $40K |
| 86480 | <1% | 799 | $40K | |
| 81001 | <1% | 14,662 | $39K | |
| 82570 | <1% | 8,974 | $39K | |
| 87340 | <1% | 3,000 | $39K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 886 | $32K |
| 86140 | <1% | 7,018 | $31K | |
| 83540 | <1% | 5,109 | $30K | |
| 83516 | <1% | 3,144 | $28K | |
| 85651 | <1% | 6,161 | $26K | |
| 86328 | <1% | 634 | $26K | |
| 80069 | <1% | 3,319 | $25K | |
| 87184 | <1% | 2,893 | $25K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 1,491 | $24K |
| 87088 | <1% | 2,289 | $24K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 570 | $24K |
| 86038 | <1% | 1,576 | $23K | |
| 82043 | <1% | 5,850 | $21K | |
| 83880 | <1% | 1,406 | $21K | |
| 86225 | <1% | 1,864 | $21K | |
| 83550 | <1% | 2,630 | $21K | |
| 82784 | <1% | 1,732 | $19K | |
| 84702 | <1% | 2,229 | $18K | |
| 84481 | <1% | 1,939 | $18K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 260 | $18K |
| 83001 | <1% | 1,056 | $18K | |
| 84146 | <1% | 1,405 | $17K | |
| 86706 | <1% | 1,203 | $16K | |
| 82746 | <1% | 1,359 | $15K | |
| 86160 | <1% | 1,139 | $14K | |
| 80076 | <1% | 1,890 | $14K | |
| 85610 | <1% | 3,794 | $13K | |
| 80074 | <1% | 345 | $13K | |
| 86769 | <1% | 280 | $12K | |
| 84466 | <1% | 1,358 | $11K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 131 | $11K |
| 82105 | <1% | 718 | $11K | |
| 86431 | <1% | 1,517 | $10K | |
| 86850 | <1% | 1,964 | $10K | |
| 86200 | <1% | 932 | $10K | |
| 83735 | <1% | 1,563 | $9K | |
| 86901 | <1% | 2,045 | $9K | |
| 82950 | <1% | 1,865 | $8K | |
| 82550 | <1% | 1,477 | $8K | |
| 87070 | <1% | 1,451 | $8K | |
| 86003 | <1% | 886 | $7K | |
| 84156 | <1% | 3,268 | $7K | |
| 85730 | <1% | 1,252 | $7K | |
| 86593 | <1% | 1,760 | $7K | |
| 84165 | <1% | 686 | $7K | |
| 86900 | <1% | 2,052 | $7K | |
| 81003 | <1% | 3,243 | $7K | |
| 87505 | <1% | 71 | $6K | |
| 84550 | <1% | 1,537 | $6K | |
| 87522 | Neg quan hep c or qual rna | <1% | 110 | $6K |
| 83525 | <1% | 699 | $6K | |
| 86334 | <1% | 219 | $6K | |
| 87205 | <1% | 1,659 | $5K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 28,725 | $5K |
| 87338 | <1% | 282 | $5K | |
| 82533 | <1% | 369 | $5K | |
| 86762 | <1% | 563 | $4K | |
| 86787 | <1% | 307 | $4K | |
| 83883 | <1% | 225 | $4K | |
| 87529 | <1% | 93 | $4K | |
| 83690 | <1% | 617 | $4K | |
| 83002 | <1% | 467 | $4K | |
| 82785 | <1% | 540 | $4K | |
| 84480 | <1% | 406 | $4K | |
| 82274 | <1% | 363 | $4K | |
| 82670 | <1% | 340 | $3K | |
| 81025 | <1% | 1,311 | $3K | |
| 82951 | <1% | 258 | $3K | |
| 87077 | <1% | 712 | $3K | |
| 87209 | <1% | 167 | $2K | |
| 85007 | <1% | 704 | $2K | |
| 84144 | <1% | 234 | $2K | |
| 83993 | <1% | 169 | $2K | |
| 84403 | <1% | 75 | $2K | |
| 84100 | <1% | 440 | $2K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 37 | $2K |
| 84154 | <1% | 117 | $2K | |
| 81015 | <1% | 629 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 144 | $1K |
| 86704 | <1% | 89 | $1K | |
| 87177 | <1% | 165 | $1K | |
| 83615 | <1% | 209 | $1K | |
| 82248 | <1% | 278 | $998.34 | |
| 86141 | <1% | 63 | $995.34 | |
| 86765 | <1% | 121 | $949.38 | |
| 86316 | <1% | 78 | $796.50 | |
| 86376 | <1% | 98 | $790.96 | |
| 87206 | <1% | 189 | $776.51 | |
| 86735 | <1% | 58 | $703.18 | |
| 87517 | <1% | 13 | $672.62 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 15 | $542.46 |
| 80306 | <1% | 45 | $480.99 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 31 | $436.43 |
| 82952 | <1% | 113 | $410.61 | |
| 87075 | <1% | 36 | $405.54 | |
| 84460 | <1% | 91 | $399.70 | |
| 85045 | <1% | 161 | $383.25 | |
| 87045 | <1% | 29 | $379.65 | |
| 84436 | <1% | 60 | $365.91 | |
| 85379 | <1% | 44 | $314.24 | |
| 87046 | <1% | 132 | $288.06 | |
| 80164 | <1% | 26 | $176.08 | |
| 84450 | <1% | 39 | $171.56 | |
| 87116 | <1% | 12 | $137.14 | |
| 83013 | <1% | 13 | $102.02 | |
| 82947 | <1% | 30 | $101.74 | |
| 84478 | <1% | 13 | $60.71 | |
| 85018 | <1% | 24 | $54.89 | |
| 86308 | <1% | 12 | $53.16 | |
| 3051F | 0% | 131 | $0.00 | |
| 3044F | 0% | 74 | $0.00 | |
| 3052F | 0% | 28 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.